Tumor-induced endothelial cell surface heterogeneity directly affects endothelial cell escape from a cell-mediated immune response in vitro

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 1, 2013, Pages 198-209

  Lokhov, Petr G ^a,c   Balashova, Elena E ^b,c  

^a INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^b INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^c ZAO BioBohemia   (Russian Federation)

Author keywords

Antiangiogenic cancer vaccine; Cell heterogeneity; Cell proteomic footprinting; Cell surface profiling; Microvascular endothelial cells; Vaccine design

Indexed keywords

CELL ANTIGEN; ENDOTHELIAL CELL ASSOCIATION ANTIGEN; FIBROBLAST ASSOCIATED ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ANTIANGIOGENIC ACTIVITY; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNITY; CELL DEATH; CELL GROWTH; CELL HETEROGENEITY; CELL INTERACTION; CELL PROLIFERATION; CELL STIMULATION; CELL STRAIN HEPG2; CELL STRAIN LNCAP; CELL STRAIN MCF 7; CELL SURFACE; CELLULAR IMMUNITY; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG DESIGN; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHALAMUS; IMMUNOGENICITY; IN VITRO STUDY; MALE; MASS SPECTROMETRY; MICROVASCULAR ENDOTHELIAL CELL; PHENOTYPIC VARIATION; TISSUE SPECIFICITY;

ANTIANGIOGENIC CANCER VACCINE; CELL HETEROGENEITY; CELL PROTEOMIC FOOTPRINTING; CELL SURFACE PROFILING; MICROVASCULAR ENDOTHELIAL CELLS; VACCINE DESIGN;

ADULT; CELLS, CULTURED; COCULTURE TECHNIQUES; ENDOTHELIAL CELLS; FEMALE; HUMANS; IMMUNE EVASION; MALE; MASS SPECTROMETRY; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84874694311     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.22828     Document Type: Article

References (69)

1. Lollini PL, Cavallo F, Nanni P, Forni G. Vaccines for tumour prevention. Nat Rev Cancer 2006; 6:204-16; PMID:16498443; http://dx.doi.org/10.1038/nrc1815.
2. No-authors-listed. Trial watch: Progress for Phase III cancer vaccines. Nat Rev Drug Discov 2008; 7:966-7; PMID:19043443; http://dx.doi.org/10.1038/ nrd2766.
3. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390:404-7; PMID:9389480; http://dx.doi.org/10.1038/37126.
4. Bussolino F, Arese M, Audero E, Giraudo E, Marchiò S, Mitola S, et al. Biological aspects of tumour angiogenesis. Cancer Modelling and Simulation. London: Chapman and Hall/CRC; 2003. p. 1-22.
5. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-6; PMID:4938153; http://dx.doi.org/10.1056/NEJM197111182852108.
6. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82:4-6; PMID:1688381; http://dx.doi.org/10.1093/jnci/82. 1.4.
7. Pluda JM. Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies. Semin Oncol 1997; 24:203-18; PMID:9129690.
8. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407:249-57; PMID:11001068; http://dx.doi.org/10.1038/35025220.
9. Copier J, Dalgleish A. Overview of tumor cell-based vaccines. Int Rev Immunol 2006; 25:297-319; PMID:17169778; http://dx.doi.org/10.1080/ 08830180600992472.
10. Wei YQ, Wang QR, Zhao X, Yang L, Tian L, Lu Y, et al. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med 2000; 6:1160-6; PMID:11017149; http://dx.doi.org/10.1038/80506.
11. Scappaticci FA, Nolan GP. Induction of anti-tumor immunity in mice using a syngeneic endothelial cell vaccine. Anticancer Res 2003; 23(2B):1165-72; PMID:12820367.
12. Corsini E, Gelati M, Calatozzolo C, Alessandri G, Frigerio S, De Francesco M, et al. Immunotherapy with bovine aortic endothelial cells in subcutaneous and intracerebral glioma models in rats: effects on survival time, tumor growth, and tumor neovascularization. Cancer Immunol Immunother 2004; 53:955-62; PMID:15449042; http://dx.doi.org/10.1007/s00262-004-0529-5.
13. Okaji Y, Tsuno NH, Kitayama J, Saito S, Takahashi T, Kawai K, et al. Vaccination with autologous endothelium inhibits angiogenesis and metastasis of colon cancer through autoimmunity. Cancer Sci 2004; 95:85-90; PMID:14720332; http://dx.doi.org/10.1111/j.1349-7006.2004.tb03175.x.
14. Chen XY, Zhang W, Zhang W, Wu S, Bi F, Su YJ, et al. Vaccination with viable human umbilical vein endothelial cells prevents metastatic tumors by attack on tumor vasculature with both cellular and humoral immunity. Clin Cancer Res 2006; 12:5834-40; PMID:17020991; http://dx.doi.org/10.1158/1078-0432.CCR- 06-1105.
15. Okaji Y, Tsuno NH, Saito S, Yoneyama S, Tanaka M, Nagawa H, et al. Vaccines targeting tumour angiogenesis-a novel strategy for cancer immunotherapy. Eur J Surg Oncol 2006; 32:363-70; PMID:16520018; http://dx.doi.org/10.1016/j.ejso.2006.01.016.
16. Aird WC. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res 2007; 100:158-73; PMID:17272818; http://dx.doi.org/10.1161/01.RES.0000255691.76142.4a.
17. Aird WC. Phenotypic heterogeneity of the endothelium: II. Representative vascular beds. Circ Res 2007; 100:174-90; PMID:17272819; http://dx.doi.org/10. 1161/01.RES.0000255690.03436.ae.
18. St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, et al. Genes expressed in human tumor endothelium. Science 2000; 289:1197-202; PMID:10947988; http://dx.doi.org/10.1126/science. 289.5482.1197.
19. Khodarev NN, Yu J, Labay E, Darga T, Brown CK, Mauceri HJ, et al. Tumour-endothelium interactions in co-culture: coordinated changes of gene expression profiles and phenotypic properties of endothelial cells. J Cell Sci 2003; 116:1013-22; PMID:12584245; http://dx.doi.org/10.1242/jcs.00281.
20. Bhati R, Patterson C, Livasy CA, Fan C, Ketelsen D, Hu Z, et al. Molecular characterization of human breast tumor vascular cells. Am J Pathol 2008; 172:1381-90; PMID:18403594; http://dx.doi.org/10.2353/ajpath.2008.070988.
21. Hellebrekers DM, Castermans K, Viré E, Dings RP, Hoebers NT, Mayo KH, et al. Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications. Cancer Res 2006; 66:10770-7; PMID:17108113; http://dx.doi.org/10.1158/0008-5472.CAN-06-1609.
22. Hellebrekers DM, Jair KW, Viré E, Eguchi S, Hoebers NT, Fraga MF, et al. Angiostatic activity of DNA methyltransferase inhibitors. Mol Cancer Ther 2006; 5:467-75; PMID:16505122; http://dx.doi.org/10.1158/1535-7163.MCT-05-0417.
23. Hellebrekers DM, Melotte V, Viré E, Langenkamp E, Molema G, Fuks F, et al. Identification of epigenetically silenced genes in tumor endothelial cells. Cancer Res 2007; 67:4138-48; PMID:17483324; http://dx.doi.org/10.1158/ 0008-5472.CAN-06-3032.
24. Unger RE, Oltrogge JB, von Briesen H, Engelhardt B, Woelki U, Schlote W, et al. Isolation and molecular characterization of brain microvascular endothelial cells from human brain tumors. In Vitro Cell Dev Biol Anim 2002; 38:273-81; PMID:12418924; http://dx.doi.org/10.1290/1071-2690(2002)038<0273: IAM COB>2.0.CO;2.
25. Bussolati B, Deambrosis I, Russo S, Deregibus MC, Camussi G. Altered angiogenesis and survival in human tumor-derived endothelial cells. FASEB J 2003; 17:1159-61; PMID:12709414.
26. Kern PA, Knedler A, Eckel RH. Isolation and culture of microvascular endothelium from human adipose tissue. J Clin Invest 1983; 71:1822-9; PMID:6306056; http://dx.doi.org/10.1172/JCI110937.
27. Maciag T, Cerundolo J, Ilsley S, Kelley PR, Forand R. An endothelial cell growth factor from bovine hypothalamus: identification and partial characterization. Proc Natl Acad Sci USA 1979; 76:5674-8; PMID:293671; http://dx.doi.org/10.1073/pnas.76.11.5674.
28. Kumar S, West DC, Ager A. Heterogeneity in endothelial cells from large vessels and microvessels. Differentiation 1987; 36:57-70; PMID:2451631; http://dx.doi.org/10.1111/j.1432-0436.1987. tb00181.x.
29. Lang I, Pabst MA, Hiden U, Blaschitz A, Dohr G, Hahn T, et al. Heterogeneity of microvascular endothelial cells isolated from human term placenta and macrovascular umbilical vein endothelial cells. Eur J Cell Biol 2003; 82:163-73; PMID:12751902; http://dx.doi.org/10.1078/0171-9335-00306.
30. Shreeniwas R, Ogawa S, Cozzolino F, Torcia G, Braunstein N, Butura C, et al. Macrovascular and microvascular endothelium during long-term hypoxia: alterations in cell growth, monolayer permeability, and cell surface coagulant properties. J Cell Physiol 1991; 146:8-17; PMID:1990021; http://dx.doi.org/10. 1002/jcp.1041460103.
31. Hewett PW. Identification of tumour-induced changes in endothelial cell surface protein expression: an in vitro model. Int J Biochem Cell Biol 2001; 33:325-35; PMID:11312103; http://dx.doi.org/10.1016/S1357-2725(01)00020-6.
32. Swerlick RA, Lee KH, Wick TM, Lawley TJ. Human dermal microvascular endothelial but not human umbilical vein endothelial cells express CD36 in vivo and in vitro. J Immunol 1992; 148:78-83; PMID:1370173.
33. Swerlick RA, Lee KH, Li LJ, Sepp NT, Caughman SW, Lawley TJ. Regulation of vascular cell adhesion molecule 1 on human dermal microvascular endothelial cells. J Immunol 1992; 149:698-705; PMID:1378077.
34. Lee KH, Lawley TJ, Xu YL, Swerlick RA. VCAM-1, ELAM-1-, and ICAM-1-independent adhesion of melanoma cells to cultured human dermal microvascular endothelial cells. J Invest Dermatol 1992; 98:79-85; PMID:1370233; http://dx.doi.org/10.1111/1523-1747.ep12495643.
35. Pötzsch B, Grulich-Henn J, Rössing R, Wille D, Müller-Berghaus G. Identification of endothelial and mesothelial cells in human omental tissue and in omentum-derived cultured cells by specific cell markers. Lab Invest 1990; 63:841-52; PMID:1701509.
36. Hewett PW, Murray JC, Price EA, Watts ME, Woodcock M. Isolation and characterization of microvessel endothelial cells from human mammary adipose tissue. In Vitro Cell Dev Biol Anim 1993; 29A:325-31; PMID:7686548; http://dx.doi.org/10.1007/BF02633961.
37. Hull MA, Hewett PW, Brough JL, Hawkey CJ. Isolation and culture of human gastric endothelial cells. Gastroenterology 1996; 111:1230-40; PMID:8898637; http://dx.doi.org/10.1053/gast.1996. v111.pm8898637.
38. Hewett PW, Murray JC. Immunomagnetic purification of human microvessel endothelial cells using Dynabeads coated with monoclonal antibodies to PECAM-1. Eur J Cell Biol 1993; 62:451-4; PMID:7925500.
39. Hewett PW, Murray JC. Human omental mesothelial cells: a simple method for isolation and discrimination from endothelial cells. In Vitro Cell Dev Biol 1994; 30:145-7; http://dx.doi.org/10.1007/BF02631436.
40. Jin Y, Liu Y, Antonyak M, Peng X. Isolation and characterization of vascular endothelial cells from murine heart and lung. Methods Mol Biol 2012; 843:147-54; PMID:22222529; http://dx.doi.org/10.1007/978-1-61779-523-7-14.
41. Jankowski R. A Comparison of Commercially-Available Human Skeletal Muscle Cells and Media for Research Applications. [Application Notes]. Nat Methods 2011.
42. Lokhov PG, Balashova EE. Cellular cancer vaccines: an update on the development of vaccines generated from cell surface antigens. J Cancer 2010; 1:230-41; PMID:21151581; http://dx.doi.org/10.7150/jca.1.230.
43. Thompson PL, Dessureault S. In: Shurin MR, Smolkin YS, editors. Immune-Mediated Diseases From Theory to Therapy New York: Springer; 2007. p. 345-55.
44. de Gruijl TD, van den Eertwegh AJ, Pinedo HM, Scheper RJ. Whole-cell cancer vaccination: from autologous to allogeneic tumor-and dendritic cellbased vaccines. Cancer Immunol Immunother 2008; 57:1569-77; PMID:18523771; http://dx.doi.org/10.1007/s00262-008-0536-z.
45. Chiang CL, Benencia F, Coukos G. Whole tumor antigen vaccines. Semin Immunol 2010; 22:132-43; PMID:20356763; http://dx.doi.org/10.1016/j. smim.2010.02.004.
46. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15:5323-37; PMID:19723653; http://dx.doi.org/10.1158/1078-0432.CCR-09-0737.
47. Lang JM, Andrei AC, McNeel DG. Prioritization of cancer antigens: keeping the target in sight. Expert Rev Vaccines 2009; 8:1657-61; PMID:19943761; http://dx.doi.org/10.1586/erv.09.134.
48. Balashova EE, Lokhov PG. Proteolytically-cleaved fragments of cell surface proteins stimulate a cytotoxic immune response against tumor-activated endothelial cells in vitro. J Cancer Sci Ther. 2010; 2:126-31; http://dx.doi.org/10.4172/1948-5956.1000037.
49. Balashova EE, Lokhov PG. Proteolytically-cleaved fragments of cell-surface proteins from live tumor cells stimulate anti-tumor immune response in vitro. Journal of Carcinogenesis & Mutagenesis. 2010; 1:1-3; http://dx.doi.org/10.4172/2157-2518.1000103.
50. Balashova EE, Dashtiev MI, Lokhov PG. Proteomic footprinting of drug-treated cancer cells as a measure of cellular vaccine efficacy for the prevention of cancer recurrence. Mol Cell Proteomics 2012; 11:M111, 014480; PMID:22074704; http://dx.doi.org/10.1074/mcp.M111.014480.
51. Lokhov P, Balashova E, Dashtiev M. Cell proteomic footprint. Rapid Commun Mass Spectrom 2009; 23:680-2; PMID:19184978; http://dx.doi.org/10.1002/rcm. 3928.
52. Nolan KF, Yun CO, Akamatsu Y, Murphy JC, Leung SO, Beecham EJ, et al. Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA. Clin Cancer Res 1999; 5:3928-41; PMID:10632322.
53. Yun CO, Nolan KF, Beecham EJ, Reisfeld RA, Junghans RP. Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors. Neoplasia 2000; 2:449-59; PMID:11191112; http://dx.doi.org/10.1038/ sj.neo.7900108.
54. Ludewig B, Ochsenbein AF, Odermatt B, Paulin D, Hengartner H, Zinkernagel RM. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J Exp Med 2000; 191:795-804; PMID:10704461; http://dx.doi.org/10.1084/jem.191.5.795.
55. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298:850-4; PMID:12242449; http://dx.doi.org/10.1126/science. 1076514.
56. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003; 100:8372-7; PMID:12826605; http://dx.doi.org/10. 1073/pnas.1533209100.
57. Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyteassociated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 2005; 12:1005-16; PMID:16283570; http://dx.doi.org/10.1245/ASO. 2005.03.536.
58. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005; 23:6043-53; PMID:16087944; http://dx.doi.org/10.1200/JCO.2005.06.205.
59. Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003; 3:630-41; PMID:12974478; http://dx.doi.org/10.1038/nri1150.
60. Paczesny S, Shi H, Saito H, Mannoni P, Fay J, Banchereau J, et al. Measuring melanoma-specific cytotoxic T lymphocytes elicited by dendritic cell vaccines with a tumor inhibition assay in vitro. J Immunother 2005; 28:148-57; PMID:15725959; http://dx.doi.org/10.1097/01.cji.0000154247.97254.ef.
61. Ossevoort MA, Feltkamp MC, van Veen KJ, Melief CJ, Kast WM. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J Immunother Emphasis Tumor Immunol 1995; 18:86-94; PMID:8574470; http://dx.doi.org/10.1097/ 00002371-199508000-00002.
62. Bodey B, Bodey B Jr., Siegel SE, Kaiser HE. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Anticancer Res 2000; 20:2665-76; PMID:10953341.
63. Schreiber TH, Raez L, Rosenblatt JD, Podack ER. Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art. Semin Immunol 2010; 22:105-12; PMID:20226686; http://dx.doi.org/10.1016/j.smim.2010.02.001.
64. Hutley LJ, Herington AC, Shurety W, Cheung C, Vesey DA, Cameron DP, et al. Human adipose tissue endothelial cells promote preadipocyte proliferation. Am J Physiol Endocrinol Metab 2001; 281:E1037-44; PMID:11595661.
65. Folkman J, Haudenschild CC, Zetter BR. Long-term culture of capillary endothelial cells. Proc Natl Acad Sci USA 1979; 76:5217-21; PMID:291937; http://dx.doi.org/10.1073/pnas.76.10.5217.
66. Rittié L, Fisher GJ. Isolation and culture of skin fibroblasts. Methods Mol Med 2005; 117:83-98; PMID:16118447.
67. Romani N, Gruner S, Brang D, Kämpgen E, Lenz A, Trockenbacher B, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994; 180:83-93; PMID:8006603; http://dx.doi.org/10.1084/jem.180.1.83.
68. John J, Dalgleish A, Melcher A, Pandha H. Cryopreserved dendritic cells for intratumoral immunotherapy do not require re-culture prior to human vaccination. J Immunol Methods 2005; 299:37-46; PMID:15890354; http://dx.doi.org/10.1016/j. jim.2004.12.014.
69. Yun CO, Nolan KF, Beecham EJ, Reisfeld RA, Junghans RP. Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors. Neoplasia 2000; 2:449-59; PMID:11191112; http://dx.doi.org/10.1038/ sj.neo.7900108.